A RANDOMIZED, DOUBLE BLIND THIRD PARTY OPEN PLACEBO-CONTROLLED EXPLORATORY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SINGLE DOSES OF PF-05089771 IN PATIENTS WITH PRIMARY (INHERITED) ERYTHROMELALGIA
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs PF 5089771 (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Feb 2013 Planned End Date changed from 1 Dec 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 27 Jan 2013 New trial record